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Abstract
Introduction: The aim of this study was to assess the cost-utility of palivizumab versus no
prophylaxis in the prevention of respiratory syncytial virus infection among high-risk preterm
infants.
Methods: We used and adapted a pre-existent model in which two cohorts of patients received
palivizumab or no prophylaxis. The patients were followed for their expected lifetimes. The
economic evaluation was conducted from the perspective of the Italian National Health Service.
We considered Life-Years Gained (LYGs), Quality-Adjusted Life-Years (QALYs) and direct medical
costs (pharmacological treatment, hospitalization, recurrences for wheezing, etc.). LYGs and
QALYs were based on the results of a double blind cohort study with prospective follow-up and
direct medical costs were based on Italian treatment patterns. Benefits and costs were discounted
at 3%. Costs were assessed in 2007 Euros. Sensitivity and threshold analysis on key clinical and
economic parameters were performed.
Result: For the two cohorts, the expected life-years (per patient) with palivizumab versus no
prophylaxis were 29.842 and 29.754 years, respectively. Quality-adjusted life years (per patient)
with palivizumab were 29.202, and for no prophylaxis were 29.043. The expected cost (per patient)
was € 6,244.20 with palivizumab and € 4,867.70 with no prophylaxis. We calculated for palivizumab
versus no prophylaxis the incremental cost per LYG and per QALY gained. It was € 15,568.65 and
€ 8,676.74, respectively.
Conclusion: This study suggests that, compared with no prophylaxis, palivizumab is cost-effective
in the prevention of respiratory syncytial virus infection among high risk preterm infants.
Background
Respiratory Syncytial Virus (RSV) is the most common
cause of viral respiratory tract infections in infancy. [1]
The common presentation of RSV on infants are lower res-
piratory tract infections such as pneumonias and bronchi-
olitis occurring usually during the first two years of life. [2-
6]
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In Italy about 4–5,000 RSV-infected, high-risk, preterm
infants (gestational age < 36 weeks, with or without bron-
chopulmonary dysplasia [BPD]) are hospitalized every
year. A proportion of these infants require admission to
intensive care units due to severity of the condition and
the level of care needed. [7] Mortality rates in hospitalized
infants are high, reaching almost 4% during the first year
of life. [8]
Several prospective clinical studies have moreover dem-
onstrated a strong correlation between RSV and recurrent
wheezing/asthma episodes. These studies have more spe-
cifically noted that the airway hyperreactivity rate is higher
by 50%–100% in RSV-infected infants compared to non-
infected children.[9] Presence of recurrent wheezing epi-
sodes was observed through the age of 11 years, possibly
extending throughout early adolescence.[4,6]
In these past few years, the launch of the intramuscular
humanized monoclonal antibody, palivizumab, has
added to the therapeutic options available for RSV proph-
ylaxis. This molecule demonstrated clinical efficacy and
satisfactory tolerability. [10-13]
In consideration of the above, Simoes et al. [14] con-
ducted a double blind cohort study with prospective fol-
low-up to verify whether administration of palivizumab
in high-risk preterm infants was capable not only of pre-
venting RSV infections but also of reducing the number of
possible subsequent recurrent wheezing episodes. Inci-
dence rates of physician-diagnosed recurrent wheezing
episodes over the 2-year duration of the study in preterm
patients not requiring RSV hospitalization were noted to
be significantly lower in the group of preterm infants
receiving palivizumab prophylaxis rather than in children
with no prophylaxis, showing rates of 8% versus  16%,
respectively (p = 0,011).
In consideration of the findings obtained by Simoes et al.
[14], it was considered appropriate to update the results of
a prior cost-effectiveness analysis [15] comparing palivi-
zumab versus absence of prophylaxis in the prevention of
RSV infections in preterm infants of different gestational
ages (less than 33 weeks, and 33 to 35 weeks) with or
without complications (BPD).
The present study intended to assess quality-adjusted and
non-adjusted incremental cost-effectiveness ratios per
year of life for palivizumab versus non-prophylaxis in the
prevention of RSV infections in high-risk preterm infants.
Methods
Background
The incremental cost-effectiveness analysis (Incremental
Cost Effectiveness Ratio – ICER) was conducted from the
perspective of the National Health System (NHS) taking
into account the direct health care expenditure assessed in
2007 euros. Life-years (LY) and QALYs (Quality-Adjusted
Life-Years) are the two outcomes assessed by the decision-
making model. As a lifetime horizon was used in the
study, a 3% discount rate was applied both to expenditure
and outcomes. In particular, costs associated with proph-
ylaxis and absence of prophylaxis were assessed for the
first two years after enrollment.
Model
In order to estimate cost-effectiveness ratios for palivizu-
mab versus non-prophylaxis, a pre-existing decision-mak-
ing tree model [15] (Figure 1) was updated based on the
results published by Simoes et al. [14]
Figure 2 describes the development of only one of the pos-
sible branches foreseen by the decision-making model
("Prophylaxis – < 33 weeks"), since branches are all equiv-
alent in terms of structure and are differentiated only in
terms of the different odds assigned to the probabilistic
nodes and the different health care expenditure.
The course of the "Prophylaxis, < 33 weeks" branch fore-
sees that infants may or may not develop an RSV infection
with ensuing hospitalization within 12 months post
administration of prophylaxis. Based on the severity of
the pediatric patient's conditions, he/she may be hospital-
ized in the ordinary ward (OW) or in the Intensive Care
Unit (ICU). In either case, OW or ICU, preterm infants
might die due to RSV. Subsequently, after the first hospi-
talization and once again within the 12 months following
administration of prophylaxis, survivors might experience
infection-related sequelae requiring rehospitalization or
leading to death. Finally, patients who survive are fol-
lowed for further 12 months to assess chances of develop-
ing recurrent wheezing episode 24 months after
prophylaxis with palivizumab.
On the other hand, in the event pediatric patients are not
immediately hospitalized due to RSV infection, the model
foresees the possibility of hospitalizations (and the relat-
ing respiratory infection-related mortality rate) within the
12-month period following enrollment (administration
of prophylaxis) and of recurrent wheezing episodes in the
subsequent 24 months.
Probability of events
The probabilities of occurrence of events considered in the
present study (Tables 1 and 2) are equal to those used in
the original model [15], except for the probability of
developing recurrent wheezing in the 24 months of fol-
low-up after the enrolment.Italian Journal of Pediatrics 2009, 35:4 http://www.ijponline.net/content/35/1/4
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The latter clinical finding was calculated based on the
results published by Simoes et al. [14]. The probability of
developing recurrent wheezing in patients who were not
hospitalized for RSV was noted to be 8% for palivizumab-
treated subjects and 16% in subjects who did not receive
prophylaxis. The data published by Simoes et al. [14]
made it possible to calculate a 17% probability of devel-
oping recurrent wheezing in subjects who where hospital-
ized for RSV and who did not receive prophylaxis (13/76
patients). In order to complete the population of the
present simulation model, the decision was taken to set at
a conservative 17% the odds of developing recurrent
wheezing in the 24 months of follow-up after the enrol-
ment also for RSV-hospitalized patients treated with pal-
ivizumab; the odds being equal to the probability for
patients without prophylaxis (Table 2).
Use of Resources
As with the original model, the use of resources refers to
administration of prophylaxis, any hospitalizations
required to treat RSV infections and treatment for recur-
rent wheezing.
Outcome
The present decision-making model, in accordance with
the original study [15], has provided an estimate of life-
years based on the various mortality odds associated with
the different probabilistic nodes for patients with or with-
out prophylaxis.
Even quality-adjusted life-years (QALY) were estimated
based on the method used in the original study. [15] They
were calculated by adding, for the expected average life
span, quality-weighted duration of the disease associated
with the presence or absence of RSV [16,17](Table 3).
Costs
The € 3,099.84 cost for prophylaxis with palivizumab was
calculated based on NHS reimbursements rates [18], and
on the administration scheme foreseeing a recommended
dosage of 15 mg per kilogram. The model is based on a
palivizumab administration scheme of one 50 mg vial/
month for the first three months and one 100 mg vial/
month for the subsequent two months, for an overall cost
of € 3,099.84. The overall dosage was calculated based on
a conservative usage hypothesis, in other words expendi-
ture includes also any unused active principle.
Appreciation of hospitalization-related costs was based
on the Interregional tariff agreement (Tariffa Unica Con-
venzionale). [19] In particular, with respect to RSV infec-
tion hospitalization in ordinary wards, DRG 98 was taken
into account – Bronchitis and asthma, age < 18 years –
equal to € 1,328.22, whereas for RSV admission to Inten-
sive Care, reference was made to DRG 475- Diagnoses
relating to the respiratory system with mechanical ventila-
tion – equal to € 8,158.90. Finally for hospitalizations
occurring for lower respiratory tract infections subsequent
to the first hospitalization, DRG 81 – Respiratory infec-
General structure of the decision-making tree model Figure 1
General structure of the decision-making tree model.
<  33 weeks
 [+
33-35 weeks
 [+]
BPD
 [+]
Prophylaxis (palivizumab)
< 33 weeks
 [+]
33-35 weeks
 [+]
BPD
 [+]
]
 
Non-prophylaxis  
(no palivizumab) 
RSV prevention 
Branch 1 
Branch 2 
Branch 3 
Branch 4 
Branch 5 
Branch 6 Italian Journal of Pediatrics 2009, 35:4 http://www.ijponline.net/content/35/1/4
Page 4 of 12
(page number not for citation purposes)
tions and inflammations, age < 18 year – equal to €
3,729.54. [15]
Since no data are available in published studies, the
annual mean cost for the treatment of a pediatric patient
with recurrent wheezing was appreciated based on the
results of the SIRIO study [20], which had calculated the
annual mean cost of an adult patient suffering from recur-
rent wheezing with respect to the Italian clinical setting
(Table 4).
Detail of the "Prophylaxis, < 33 weeks" branch Figure 2
Detail of the "Prophylaxis, < 33 weeks" branch.
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Table 1: Risk class and probability of hospitalization
Prophylaxis Non prophylaxis
Probability of occurrence 33–35 wks < 33 wks BPD 33–35 wks < 33 wks BPD
Risk class
- patient rate 11.0% 70.0% 19.0% 11.0% 70.0% 19.0%
Probability of hospitalization
- ordinary ward 1.5% 2.0% 5.6% 9.8% 10.3% 18.4%
- Intensive therapy unit 1.3% 1.3% 1.3% 3.0% 3.0% 3.0%
From: Ravasio R et al. [15]Italian Journal of Pediatrics 2009, 35:4 http://www.ijponline.net/content/35/1/4
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Sensitivity analyses
In order to test the robustness of the estimates resulting
from the decision-making model [21] a series of univari-
ate analyses were performed on the variables producing
the greatest impact on the results of the simulation model:
palivizumab dosage scheme, annual mean cost for a
patient with recurrent wheezing and probability of devel-
oping recurrent wheezing within 24 months post-enroll-
ment. In the first case (palivizumab dosage) the univariate
analysis was conducted based on the assumption of a
prophylaxis scheme with five monthly 100 mg injections,
contrary to the base case scenario (three 50 mg adminis-
trations and two 100 mg administrations). The annual
mean cost for a patient with recurrent wheezing changed
based on the limits of the respective Confidence Interval
(CI 95%, € 1,054.34 – € 1,399.42), whereas the probabil-
ity of developing recurrent wheezing within 24 months
post-enrolment was adjusted by ± 10% compared to its
base value [21] assuming the worst case scenario for pal-
ivizumab (+10% [least advantageous] compared to the
base value for the "Prophylaxis" branch and -10% [more
advantageous] for the "Non prophylaxis" branch).
Finally, a threshold analysis was conducted on the proba-
bility of an RSV hospitalization occurring in patients
receiving palivizumab prophylaxis. This analysis intended
to identify which value of this parameter would show an
incremental cost per life year (quality weighted and non-
quality weighted) equal to € 50.000 in the simulation
model, considering the latter value to represent the
threshold below which a therapy would be considered
acceptable. [22]
Results
Life years (LY) and QALY (3% discount)
Patients receiving palivizumab prophylaxis show better
efficacy results measured in terms both of LYs (+ 0.088)
and of QALYs (+ 0.159) [Table 5]. Such an advantage, ver-
sus the absence of prophylaxis comparator, is maintained
even when analyzing the results for the comparisons on
patient subgroups (BPD, < 33 weeks, 33–35 weeks) [Table
5].
Total treatment costs (3% discount)
The annual mean cost per patient receiving prophylaxis (€
6,244.20) exceeds by € 1,376.50 the cost estimated for a
non-prophylaxis patient (€ 4,867.70) [Table 6]. The same
result is apparent also in comparisons across patient sub-
groups, with differences between the two therapeutic
options ranging from € 513.47 to € 2,220.09.
Table 2: Probability of events following the first hospitalization and number of events
RSV-hospitalized subjects Subjects without RSV-hospitalization
Probability of occurrence 33–35 wks < 33 wks BPD 33–35 wks < 33 wks BPD
Probability of events following the first hospitalization
- hospitalization during the first 12 months after enrolment 100.0% 100.0% 100.0% 60.0% 60.0% 60.0%
- mortality throughout the first 12 months 4.0% 4.0% 4.0% 0.8% 0.8% 0.8%
- probability of developing recurrent wheezing throughout the 24 
months following enrolment with palivizumab [14]
17.0%* 17.0%* 17.0%* 8.0% 8.0% 8.0%
- probability of developing recurrent wheezing throughout the 24 
months following enrolment without palivizumab [14]
17.0% 17.0% 17.0% 16.0% 16.0% 16.0%
Events
- no. of hospitalizations due to respiratory causes during the first 
12 months after enrollment
2.89 5.40 5.40 1.28 1.00 1.00
From: Ravasio R et al. [15]; *Conservative assumption based on study data published
Table 3: Quality of life
Variable Value
Health-related QoL score* (range 0–1)
No RSV hospitalization 0.950
RSV hospitalization 0.880
From: Greenough A et al. [16], calculations based on Health Utility 
Index 2: Torrance GW et al. [17].
*QoL = Quality of LifeItalian Journal of Pediatrics 2009, 35:4 http://www.ijponline.net/content/35/1/4
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Incremental cost-effectiveness ratio
In terms of overall data ("total mean"), the incremental
cost effectiveness ratio per LY estimated by the model was
equal to € 15,568.65, and that per QALY was € 8,676.74
(Table 7).
With respect to the secondary analysis conducted for the
three subgroups, ICERs were observed to range between €
4,332.29 – € 28,417.08 per LY, and from € 2,731.81 to €
14,937.32 for QALYs.
Sensitivity analysis
Univariate analysis
Table 8 illustrates the results of the sensitivity analysis
conducted by adjusting the base values as per the palivizu-
mab dosage scheme, the annual mean cost of a patient
with recurrent wheezing patient and the probabilities of
developing recurrent wheezing within 24 months post-
enrolment. The incremental cost effectiveness ratios per
LY or per QALY estimated by all the univariate analyses
show values lower than the internationally accepted €
50,000 threshold [22].
Amongst those taken into account, the parameter that
most affects the variability of incremental cost-effective-
ness ratios is the palivizumab dosage scheme. When mean
data ("Total") are referred to, the univariate analyses con-
ducted on this parameter show an increase of ICER versus
base values by 62.8% both per LY and QALY (Table 8).
Table 4: Annual mean cost for a patient with asthma
Expenditure Breakdown Mean cost per Patient (€)
Pharmacological therapy 457.82
Hospitalizations (ordinary admission and Day Hospital) 461.87
Admissions to Emergency Room 5.11
Visits 112.26
Examinations 127.76
Specific immune therapy 31.86
Other 30.21
Annual mean cost 1,226.88
Table 5: Results: LY and QALY (3% discount)
Parameter Prophylaxis Non prophylaxis Difference
LY
Total 29.842 29.754 0.088
- BPD 29.813 29.694 0.119
- < 33 weeks 29.849 29.771 0.078
- 33–35 weeks 29.854 29.776 0.078
QALY
Total 29.202 29.043 0.159
- BPD 29.173 28.985 0.188
- < 33 weeks. 29.209 29.060 0.150
- 33–35 weeks 29.214 29.065 0.149
Table 6: Results: mean cost per patient (3% discount)
Mean cost per treated patient
Parameter Prophylaxis Non prophylaxis Difference
- BPD 6,517.26 6,003.79 513.47
- < 33 weeks 5,819.65 4,429.13 1,390.52
- 33–35 weeks 6,199.79 3,979.70 2,220.09
Total 6,244.20 4,867.70 1,376.50Italian Journal of Pediatrics 2009, 35:4 http://www.ijponline.net/content/35/1/4
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Threshold analyses
Figures 3, 4 and 5 illustrate the results of the threshold
analyses. The three analyses were based on a simulation
reducing efficacy of palivizumab, therefore increasing the
probabilities of an RSV hospitalization in prophylaxis-
treated patients, differentiating between preterm infants
with BPD, gestational age < 33 weeks and gestational age
between 33 and 35 weeks.
In the first case (preterm BPD infants) (figure 3) the
threshold level (for hospitalizations) at which palivizu-
mab shows an incremental cost per LY of € 50,000 is
13.3% (increased by 137.5% compared to the 5.6% base
value), whereas for QALYs such value rises to 18.6% (+
232.1% compared to the base value).
In the second case (infants with gestational age < 33
weeks) (figure 4) the threshold level at which palivizu-
mab shows incremental values per LY of € 50,000 is 5.6%
(increased by 180% compared to the 2% base value), ris-
ing to 10.8% for QALYs (+440% compared to base val-
ues).
Finally, the third case (children whose gestational age
ranges between 33 and 35 weeks) (figure 5) points out a
4.3% threshold level at which Palivizumab shows an
incremental cost per LY of € 50,000 (increased by 186.7%
compared to the 1.5% base value), whereas said rate rises
to 10.4% for QALYs (+ 593.3% compared to base value).
Discussion
The present analysis assessed efficacy and costs of proph-
ylaxis with palivizumab versus absence of prophylaxis in
the prevention of RSV infections in high-risk preterm
infants. The (incremental) cost-effectiveness analysis was
conducted from the perspective of the National Health
System, updating and adapting a pre-existing lifetime
decision-making model [15]. We wish to point out that as
in the previously published model, RSV infection mortal-
ity during the first hospitalization was estimated based on
the results of the IMPACT study: mortality rates were
noted to be 0.2% and 0.0% in subjects who received pal-
ivizumab prophylaxis and subjects who did not receive
prophylaxis, respectively [15]. Other probability rates of
occurrence of the events investigated in the present study
are also the same ones used in the original model [15],
with the exception of the odds of developing recurrent
wheezing within 24 months post-enrolment, data deriv-
ing from Simoes study [14].
Table 7: Results: ICER (3% discounted costs and outcomes)
Parameter ICER
LY
Total (mean) 15,568.65
- BPD 4,332.29
- < 33 weeks 17,885.86
- 33–35 weeks 28,417.08
QALY
Total (mean) 8,676.74
- BPD 2,731.81
- < 33 weeks 9,380.00
- 33–35 weeks 14,937.32
Table 8: Univariate sensitivity analysis
Parameters ICER per LY (€)I C E R  p e r  Q A L Y  ( €)
Palivizumab dosage scheme
Total 25,352.07 14,129.26
BPD 12,532.56 7,902.66
< 33 weeks 30,387.26 15,936.20
33–35 weeks 40,857.49 21,476.58
Annual mean cost per patient with recurrent wheezing
Total 15,437.90 – 15,699.62 8,603.88 – 8,749.74
BPD 4,225.56 – 4,438.94 2,664.51 – 2,799.06
< 33 weeks 17,717.48 – 18,054.36 9,291.70 – 9,468.37
33–35 weeks 28,248.76 – 28,585.65 14,848.85 – 15,025.93
Probability of developing recurrent wheezing within 24 months from enrollment
Total 15,857.51 8,837.74
BPD 4,577.05 2,886.15
< 33 weeks 18,253.99 9,573.06
33–35 weeks 28,782.64 15,129.48Italian Journal of Pediatrics 2009, 35:4 http://www.ijponline.net/content/35/1/4
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We wish to briefly describe the changes made to the orig-
inal model. Costs associated with high-risk preterm
patients refer to 24 months after enrollment instead of 14
years so as to uniform the financial evaluation to the new
data available in literature [14]. Palivizumab administra-
tion scheme was changed, with three 50 mg vials and two
100 mg vials instead of the five 100 mg vials administered
in the first model. Finally, all of the health care resources
used by the patient were revaluated based on year 2007
costs and fees.
As regards general results, patients receiving palivizumab
prophylaxis show better efficacy in terms both of LY (+
0.088) and QALY (+ 0.159) compared to those who did
not receive any prophylaxis. The best efficacy result
achieved by palivizumab is confirmed also when differen-
tiating patients per gestational age and presence of BPD.
On the other hand, in terms of the health care resources
used, the mean cost per patient receiving prophylaxis (€
6,244.20) was higher (+28.3%) compared to the esti-
mated cost per patient without prophylaxis (€ 4,867.70).
Therefore, due to the greater efficacy and greater costs
associated with palivizumab versus the comparator
(absence of prophylaxis), it was necessary to determine
the incremental cost-effectiveness ratio per LY and QALY.
The calculation of the incremental cost per life year gained
was based on an overall mean cost per patient of €
6,244.20 for palivizumab and of € 4,867.70 for absence
of prophylaxis, with a mean survival of 29.842 years and
29.754 years, respectively. The incremental cost for
prophylaxis (€ 1,376.50) was thus compared to an incre-
mental efficacy of 0.088 years, leading to a cost per life
year gained of € 15,568.65. In the case of the incremental
cost per QALY the same mean total costs were recorded
per patient (€ 6,244.20 and € 4,867.70), with however
different outcomes. Palivizumab is characterized by
29.202 QALYs and absence of prophylaxis is associated
with 29.043 QALYs. Incremental efficacy in this case is
equal to 0.159 QALYs; therefore the incremental cost per
QALY is € 8,676.74. Taking into account patient sub-
groups, the incremental cost effectiveness ratio per LY
ranges between € 4,332.29 and € 28,417.08, whereas
those per QALY range between € 2,731.81 and €
14,937.32.
All incremental costs calculated in this paper were finally
compared against internationally acknowledged thresh-
Threshold analysis: group of preterm BPD infants Figure 3
Threshold analysis: group of preterm BPD infants.Italian Journal of Pediatrics 2009, 35:4 http://www.ijponline.net/content/35/1/4
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old values, which reflect the decision-making bodies' will-
ingness to pay in order to achieve additional health units.
Several international studies addressed the issue and
established threshold values [22-25] and € 50,000 were
set as the threshold below which a therapy is acceptable.
Incremental costs per life year gained and per QALY calcu-
lated for palivizumab versus the absence of prophylaxis
were always noted to be below the aforesaid threshold.
The incremental cost per LY or per QALY of palivizumab
was quite different observing the results of the three infant
groups. The 33–35 weeks infant group showed the higher
ICER per LY (€ 28,417.08) and per QALY (€ 14,937.32).
If we considered a more restricted threshold value (< €
50,000), this third infant group (33–35 weeks) could be
included in the prophylaxis programs, provided addi-
tional risk factors are present.
The univariate analyses conducted on several clinical and
financial parameters taken into consideration in the
model confirmed the robustness of the results, producing
ICERs that were always below € 50,000. Also the thresh-
old analysis conducted on the probability of an RSV hos-
pitalization occurring for a patient receiving palivizumab
prophylaxis estimated that to reach an incremental cost
per LY or per QALY exceeding € 50,000 the efficacy of pal-
ivizumab would have to drop to non-realistic levels, i.e.,
down to efficacy levels equal to or even lower than those
for patients without prophylaxis.
These results must be compared with those generated by
other studies. Nuijten et al. [26] conducted in the United
Kingdom an incremental cost effectiveness analysis for
palivizumab in the prophylaxis of RSV infections in pre-
term infants with gestational age < 36 weeks and the pos-
sible presence of complications such as BPD or CHD
(Congenital Heart Disease). The assessment was con-
ducted from the perspective of the UK NHS (National
Health Service), comparing administration of palivizu-
mab to absence of prophylaxis. Applying a discount
(3.5%) both to costs and outcome, an incremental cost
per QALY equal to £ 16,720 for children with gestational
age < 36 weeks and for children with BPD and an ICER per
QALY of £ 6,664 for children with CHD. The results of the
study conducted by Nuijten et al. [26] suggest that from
the NHS viewpoint, palivizumab is cost effective com-
pared to the therapeutic alternative represented by
absence of prophylaxis.
Lazaro et al. [27] assessed efficacy and costs of palivizu-
mab in the prevention of RSV infections in preterm chil-
dren with gestational age in the 32–35 week range with
two or more risk factors. The study was conducted from
Threshold analysis: group of infants with gestational < 33 weeks Figure 4
Threshold analysis: group of infants with gestational < 33 weeks.Italian Journal of Pediatrics 2009, 35:4 http://www.ijponline.net/content/35/1/4
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the perspective of the Spanish health care system, with
absence of prophylaxis as the comparator. The Authors,
thanks to a decision-making model, have calculated (with
a 3% discount applied to efficacy and costs) an incremen-
tal cost effectiveness ratio per QALY of € 13,849. Once
again, palivizumab was noted to be cost-effective versus
absence of prophylaxis.
The study conducted in the USA by Elhassan et al. [28]
intended to assess both the cost-effectiveness ratio of pal-
ivizumab as RSV prophylaxis in preterm children without
BPD and the impact of decreasing recurrent wheezing
risks in patients receiving prophylaxis on the cost effec-
tiveness ratio. The Authors constructed two decision-mak-
ing models, one of which took into account also risks of
recurrent wheezing after an RSV infection and another
one that did not consider this risk. The patients included
in the model were preterm children with gestational age
ranging from 26 to 32 weeks. Prophylaxis with palivizu-
mab was compared against absence of prophylaxis. The
results of the study conducted by Elhassan et al. [28] esti-
mated that administration of palivizumab was cost effec-
tive only when taking into account also the benefits
yielded by a decreased risk of recurrent wheezing in RSV
infection patients.
The results of the present review present limitations and
therefore several considerations must be taken into
account when interpreting the data. As the study con-
ducted by Simoes et al.[14] has estimated the probabili-
ties of developing recurrent wheezing episodes during 24
months of follow-up after the enrollment in preterm chil-
dren with gestational age equal or less than 35 weeks, with
or without RSV hospitalization, the present model is
based on the assumption that such probability was iden-
tical for all children, without differentiating based on ges-
tational age and the presence of BPD. Moreover, since the
study performed by Simoes et al.[14] did not report the
odds of developing recurrent wheezing in preterm chil-
dren receiving prophylaxis with RSV hospitalization, for
this group of patients the same percentage (17%) calcu-
lated for preterm children with RSV hospitalization not
receiving prophylaxis was conservatively adopted. To
assess the impact of this double assumption, a sensitivity
analysis was performed to test the probability of develop-
ing recurrent wheezing during the 24 months of follow-
up post-enrollment, with a ± 10% change of the base
value, assuming the worst case scenario for palivizumab;
also in this case, the incremental cost effectiveness ratios
per LY and per QALY show values lower than € 50.000.
Threshold analysis: group of infants with gestational age between 33 and 35 weeks Figure 5
Threshold analysis: group of infants with gestational age between 33 and 35 weeks.Italian Journal of Pediatrics 2009, 35:4 http://www.ijponline.net/content/35/1/4
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Another limitation of the study might be that a pre-exist-
ing simulation model was adopted for the comparison
between the two alternatives, and was adapted with clini-
cal data deriving from international literature. This choice
might be justified by the fact that to date no studies are
available providing national data suitable for constructing
the model population.
The dosage scheme (three 50 mg vials + two 100 mg vials)
adopted herein for prophylaxis administration is different
from that used in the original model.[15] In support
thereof, a dosage of 15 mg of active principle per kg of
weight was considered, assuming that average weight of
the preterm infant in the first three months of life was less
than 3.4 kg, thus such as to justify the administration of a
50 mg vial; moreover the model conservatively included
also the non-administered drug. Moreover, by means of
the sensitivity analysis, also the five 100 mg vials admin-
istration assumption was taken into consideration, and
also in this case ICERs per LY and per QALY remained
lower than the € 50,000 threshold.
Finally, as already pointed out by the original study, a fur-
ther limitation might be the use of average costs referring
to an adult sample for the appreciation of the annual
mean cost for recurrent wheezing of pediatric patients.
However, comparing the cost included in the present
model (€ 1,226.88) against that of children suffering
from asthma (US$ 1,129) within a study conducted in the
United Stated in 1999 [29], we have reason to believe that
the data we used are conservative.
Conclusion
Based on the results of the present cost-effectiveness
assessment it therefore appears possible to state that com-
pared to absence of prophylaxis, the administration of
palivizumab in preterm infants of varying gestational
ages, with or without complications, does improve sur-
vival (quality-weighted or not) at reasonable costs in
terms of resources covered by the NHS, when compared to
internationally accepted threshold values. However, there
is not general consensus concerning palivizumab prophy-
laxis for preterm infants born between 32 and 35 weeks of
gestational age without chronic lung disease and haemo-
dynamically significant congenital heart disease. [22].
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